Gene Therapy in CVMD

Table of Contents
1. Preface
1.1 Related Reports 4
1.2 Upcoming Related Reports 5
1.3 Abbreviations 6
2. Executive Summary 9
2.1 Key Findings 10
2.2 KOL and Payer Insight on CVMD Gene Therapy Competitive Landscape 11
3. Overview of CVMD Gene Therapy 12
3.1 What is Gene Therapy? 14
3.2 Gene Transfer Methods and Vectors Used for Gene Therapy 18
3.3 Viral Vectors vs. Non Viral Vectors 20
3.4 Therapeutic Gene Therapy Strategies Employed in CVMD 24
3.5 Gene Therapy in the 8MM 25
4. Epidemiology Analysis 31
4.1 Coronary Artery Disease 33
4.2 Peripheral Artery Disease 34
4.3 Peripheral Artery Disease with Critical Limb Ischemia 35
4.4 Systolic Heart Failure 36
4.5 Diabetic Foot Ulcers 37
4.6 Diabetic Neuropathy 38
4.7 Pompe Disease 39
5. Pipeline Assessment 40
5.1 CVMD Gene Therapy Pipeline in the 8MM 42
5.2 Pipeline Products - Phase III 43
5.3 AnGes MG's Collategene 44
5.4 Angionetics' Generx 45
5.5 ViroMed's Donaperminogene Seltoplasmid 46
5.6 Renova's RT-100 49
5.7 Pipeline Products - Phase II 50
5.8 ID Pharma's DVC-10101 51
5.9 Juventas' JVS-100 52
5.10 UF's Gene Therapy to Activate Acid Alpha Glucosidase for Pompe Disease 54
6. Clinical Trials Mapping and Design 55
6.1 Clinical Trial Mapping 57
6.2 Clinical Trial Design 59
7. Pricing and Reimbursement Strategies - Payer Perspective 60
7.1 Current CVMD Space 62
7.2 Challenges Associated with Reimbursement of Novel CVMD Therapies 63
7.3 Prospective Payer Strategies for CVMD Gene Therapies 64
8. Market Outlook 65
8.1 Phase III CVMD Gene Therapy Pipeline 67
8.2 Key Launch Dates for Phase II and III CVMD Gene Therapy Pipeline 71
9. Appendix 72
9.1 Sources 73
9.1 Methodology 74
9.2 Primary Research 75
9.3 About the Authors 76
9.4 About GlobalData 78
9.5 Contact Us 79
9.6 Disclaimer 80